{"id":13316,"date":"2018-03-14T14:54:43","date_gmt":"2018-03-14T09:24:43","guid":{"rendered":"https:\/\/blog.fundsindia.com\/blog\/?p=13316"},"modified":"2018-03-14T14:54:43","modified_gmt":"2018-03-14T09:24:43","slug":"aurobindo-pharma-ltd","status":"publish","type":"post","link":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316","title":{"rendered":"Aurobindo Pharma Ltd"},"content":{"rendered":"<p>Aurobindo Pharma Ltd (Auro) is one of the largest vertically integrated pharmaceutical companies. Over the past few years, the company has drastically shifted its focus from APIs business to generic formulations.<\/p>\n<p><strong>Outlook and Valuation:<\/strong> We believe Aurobindo Pharma is better placed as compared to its peers on the back of relatively better performance despite pricing pressure in the US. We expect revenue and PAT to grow at a CAGR of 9.5%\/7% over FY17-20E on the back of new product launches mainly in complex generics, volume growth in existing products and ramp-up in Europe business. Importantly, recent observations of the USFDA to its unit-IV facility (which makes injectables) at Hyderabad, remains a concern. The USFDA has issued Form 483 with 9 observations to the company\u2019s unit 4, citing deficiencies in maintaining manufacturing standards. However, none of the observations are related to data integrity or are repetitive in nature. We recommend \u2018BUY\u2019 rating on the stock with a target price of Rs 644 based on 13.5x FY20E EPS<\/p>\n<p><a href=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/03\/Research-Report-Aurobindo-Pharma.pdf\">Research Report &#8211; Aurobindo Pharma<\/a><\/p>\n<p><i>Investments in equity shares, debentures, etc., are not obligations of, or guaranteed by Wealth India Financial Services Pvt. Ltd., and are subject to investment risks.\u00a0<a href=\"http:\/\/pages.fundsindia.com\/pages\/disclaimer-equities\/\">Click here<\/a>\u00a0to read our full disclaimer.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma Ltd (Auro) is one of the largest vertically integrated pharmaceutical companies. Over the past few years, the company has drastically shifted its focus from APIs business to generic formulations. Outlook and Valuation: We believe Aurobindo Pharma is better placed as compared to its peers on the back of relatively better performance despite pricing [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[59],"tags":[541],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v17.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aurobindo Pharma Ltd<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aurobindo Pharma Ltd\" \/>\n<meta property=\"og:description\" content=\"Aurobindo Pharma Ltd (Auro) is one of the largest vertically integrated pharmaceutical companies. Over the past few years, the company has drastically shifted its focus from APIs business to generic formulations. Outlook and Valuation: We believe Aurobindo Pharma is better placed as compared to its peers on the back of relatively better performance despite pricing [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316\" \/>\n<meta property=\"og:site_name\" content=\"Insights\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/fundsindia\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-14T09:24:43+00:00\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Equities Desk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\",\"name\":\"Wealth India Financial Services\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"sameAs\":[\"https:\/\/www.facebook.com\/fundsindia\"],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"contentUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"width\":189,\"height\":200,\"caption\":\"Wealth India Financial Services\"},\"image\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"name\":\"Insights\",\"description\":\"Official blog of FundsIndia.com\",\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#webpage\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316\",\"name\":\"Aurobindo Pharma Ltd\",\"isPartOf\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\"},\"datePublished\":\"2018-03-14T09:24:43+00:00\",\"dateModified\":\"2018-03-14T09:24:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fundsindia.com\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aurobindo Pharma Ltd\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#webpage\"},\"author\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\"},\"headline\":\"Aurobindo Pharma Ltd\",\"datePublished\":\"2018-03-14T09:24:43+00:00\",\"dateModified\":\"2018-03-14T09:24:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#webpage\"},\"wordCount\":205,\"commentCount\":6,\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"keywords\":[\"Aurobindo Pharma Ltd\"],\"articleSection\":[\"Equity Research\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#respond\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\",\"name\":\"Equities Desk\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"caption\":\"Equities Desk\"},\"sameAs\":[\"http:\/\/www.fundsindia.com\"],\"url\":\"https:\/\/www.fundsindia.com\/blog\/author\/equities-desk\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aurobindo Pharma Ltd","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316","og_locale":"en_US","og_type":"article","og_title":"Aurobindo Pharma Ltd","og_description":"Aurobindo Pharma Ltd (Auro) is one of the largest vertically integrated pharmaceutical companies. Over the past few years, the company has drastically shifted its focus from APIs business to generic formulations. Outlook and Valuation: We believe Aurobindo Pharma is better placed as compared to its peers on the back of relatively better performance despite pricing [&hellip;]","og_url":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316","og_site_name":"Insights","article_publisher":"https:\/\/www.facebook.com\/fundsindia","article_published_time":"2018-03-14T09:24:43+00:00","twitter_misc":{"Written by":"Equities Desk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/www.fundsindia.com\/blog\/#organization","name":"Wealth India Financial Services","url":"https:\/\/www.fundsindia.com\/blog\/","sameAs":["https:\/\/www.facebook.com\/fundsindia"],"logo":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#logo","inLanguage":"en-US","url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","contentUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","width":189,"height":200,"caption":"Wealth India Financial Services"},"image":{"@id":"https:\/\/www.fundsindia.com\/blog\/#logo"}},{"@type":"WebSite","@id":"https:\/\/www.fundsindia.com\/blog\/#website","url":"https:\/\/www.fundsindia.com\/blog\/","name":"Insights","description":"Official blog of FundsIndia.com","publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#webpage","url":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316","name":"Aurobindo Pharma Ltd","isPartOf":{"@id":"https:\/\/www.fundsindia.com\/blog\/#website"},"datePublished":"2018-03-14T09:24:43+00:00","dateModified":"2018-03-14T09:24:43+00:00","breadcrumb":{"@id":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fundsindia.com\/blog"},{"@type":"ListItem","position":2,"name":"Aurobindo Pharma Ltd"}]},{"@type":"Article","@id":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#article","isPartOf":{"@id":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#webpage"},"author":{"@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656"},"headline":"Aurobindo Pharma Ltd","datePublished":"2018-03-14T09:24:43+00:00","dateModified":"2018-03-14T09:24:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#webpage"},"wordCount":205,"commentCount":6,"publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"keywords":["Aurobindo Pharma Ltd"],"articleSection":["Equity Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fundsindia.com\/blog\/equities\/aurobindo-pharma-ltd\/13316#respond"]}]},{"@type":"Person","@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656","name":"Equities Desk","image":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#personlogo","inLanguage":"en-US","url":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","caption":"Equities Desk"},"sameAs":["http:\/\/www.fundsindia.com"],"url":"https:\/\/www.fundsindia.com\/blog\/author\/equities-desk"}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/13316"}],"collection":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/comments?post=13316"}],"version-history":[{"count":1,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/13316\/revisions"}],"predecessor-version":[{"id":13319,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/13316\/revisions\/13319"}],"wp:attachment":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/media?parent=13316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/categories?post=13316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/tags?post=13316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}